Introduction: The insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene has recently been linked to the pathogenesis and progression of human cancers. The aim of this study was to evaluate the potential association between ACE I/D polymorphism and glioma in a Chinese population. Materials and methods: A case-control study involving patients with 800 glioma and 800 controls was conducted. Polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay was applied to assess the ACE I/D genotypes. Results: Glioma cases had a significantly higher frequency of DD genotype [odds ratio (OR) = 1.61, 95% confidence interval (CI) = 1.12, 2.32; p = 0.01] than controls. When stratified by the grade of glioma, cases with WHO IV glioma had a significantly higher frequency of DD genotype (OR = 1.51, 95% CI = 1.03, 2.21; p = 0.03). When stratified by the histology of glioma, there was no significant difference in the distribution of each genotype. Conclusion: Our study suggested that the ACE DD genotype was associated with a higher glioma risk in this Chinese population. To the best of our knowledge, this is the first report describing the potential association between ACE I/D polymorphism and glioma. Additional studies are needed to confirm this finding.
Introduction
Gliomas are the most common primary tumors of the central nervous system, 1 but in spite of the marked advances in the characterization of their molecular pathogenesis, these tumors remain incurable. Estimated 5-year survival was 60% and 74% for biopsy and watchful waiting and early resection in low-grade gliomas, respectively. 2, 3 Gliomas are classified as grade I to grade IV on the basis of histopathological and clinical criteria established by the World Health Organization (WHO). 4 This group of tumors includes specific histological subtypes, the most common of which are the astrocytomas, glioblastoma, and other gliomas. [4] [5] [6] Malignant gliomas account for approximately 70% of the 22,500 new cases of malignant primary brain tumors that are diagnosed in adults in USA each year. 7 Several occupations, 8, 9 environmental carcinogens, 10 and diet have been reported to be associated with an elevated glioma risk, [11] [12] [13] [14] [15] as well as genetic factors such as single nucleotide polymorphisms (SNPs). 2 The angiotensin-converting enzyme (ACE) gene (chromosome 17q23) has functional insertion/deletion (I/D) polymorphism of a 287 bp Alu sequence within intron 16. 16 Subjects with the DD genotype have higher plasma ACE activity compared with those with the ID and II genotypes. 16, 17 The ACE I/D polymorphism has recently been linked to the pathogenesis and progression of human cancers. Although an association between ACE I/D polymorphism and glioma is biologically plausible, there is no epidemiologic study to evaluate the potential association between ACE I/D polymorphism and glioma. The aim of this study was to evaluate the potential association between ACE I/D polymorphism and glioma in a Chinese population. 
Materials and methods

Study population
From January 2009 to December 2012, 800 primary gliomas cases, from the Department of Neurosurgery of the First Affiliated Hospital of Xi'an Jiaotong University, that had been surgically resected were analyzed. At the same time, 800 healthy controls were collected from the same geographic region. This was a convenience sample, and the cases were collected consecutively. The healthy control subjects were matched with the gliomas cases for age and sex. Tumor type and stage were determined according to the WHO criteria. Smoking status was defined as non-smoker (smoked less than 100 cigarettes in lifetime) and smoker. Drinking status was defined as non-drinker and drinker (drinks per day). Informed consents were obtained according to the Declaration of Helsinki. Participants will be paid for their time. This study was approved by the institutional review board of the Xi'an Jiaotong University.
DNA extraction and genotyping
Leukocyte DNA was extracted from 10 ml of venous blood, anticoagulated with 1.6 mg/ml EDTA using a commercially available kit (Wizard DNA Purification Kit, Promega, Madison, WI, USA). A polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay was applied to assess the ACE I/D genotypes. 18 Based on the GenBank reference sequence, the PCR primers were as follows: forward-5'-CTGGAGACCACTCCCATCCTTTCT -3' and reverse-5'-GATGTGGCCATCACATTCGTCAGAT -3'. DNA was denaturanted at 94°C for 5 min, followed by 30 cycles of denaturation at 94°C for 1 min, annealing at 67°C for 1 min and extension at 72°C for 2 min, with a final extension step of 5 min at 72°C. PCR products (490 bp insertion and 190 bp deletion) were separated by 2% agarose gel electrophoresis, stained with ethidium bromide, and viewed with ultraviolet (UV) light.
Statistical analysis
Chi-square test was used to compare the genotype distribution between the two groups. Multivariate logistic regression analysis was used to assess the association between the genotypes and risk of glioma after stratifying the subjects according to age, gender, and histological grade. The odds ratio (OR) and 95% confidence interval (CI) were calculated using a logistic regression model. A 2-sided significance level of p-value less than .05 was used for all analyses. All analyses were performed using Predictive Analytics Software version 18.0 (SPSS Inc., Chicago, IL, USA) for Windows ® .
Results
The characteristics of the 800 glioma cases and 800 control subjects are shown in Table 1 . Glioma cases and controls did not differ regarding gender (p = 0.58) or age (p = 0.68). The mean age was 45.3 (± 9.7) years for the glioma and 45.1 (± 9.5) years for the controls. In addition, no significant differences between the cases and controls in smoking (p = 0.75), drinking (p = 0.79) and family history of cancer (p = 0.72) were found (Table 1) . Among 800 glioma cases, 285 cases had astrocytomas, 264 cases had glioblastoma and 251 cases had other gliomas. In these cases, 68 cases had WHO grade I gliomas, 249 cases had WHO grade II gliomas, 161 cases had WHO grade III gliomas, and 322 cases had WHO grade IV gliomas. Glioma cases had a significantly higher frequency of DD genotype (OR =1.61, 95% CI = 1.12, 2.32; p = 0.01) than controls (Table 2) . When stratified by the grade of glioma, cases with WHO IV glioma had a significantly higher frequency of DD genotype (OR =1.51, 95% CI = 1.03, 2.21; p = 0.03) ( Table 3) . When stratified by the histology of glioma, there was no significant difference in the distribution of each genotype (Table 3 ).
Discussion
The ACE I/D polymorphism has recently been linked to many other cancers. A case-control study indicated that the ACE I/D polymorphism played an important role in the risk of prostate cancer. The DD genotype was related to patients with aggressive stage of prostate cancer (OR = 2.21, 95%CI = 1.169, 4.194; p = 0.01). 19 A populationbased case-control study indicated that the D allele in the ACE gene was closely associated with a significantly higher risk of developing prostate cancer (OR = 31.66, 95%CI = 0.09, 1.27) in Mexico. 20 A case-control study showed that the ACE I/D polymorphism might be linked to the progression of human prostate cancer. It was found that the DD genotype was present in 31 of 78 (39.8%) patients with advanced disease and in 19 of 82 (23.2%) with localized disease: this difference was statistically significant (OR = 2.18, 95%CI = 1.11, 4.03, p = 0.02). 21 A populationbased case-control study suggested that the DD genotype of ACE may contribute to a higher risk of developing squamous cell carcinoma in a Croatian population. 22 A casecontrol study indicated that the ACE I/D polymorphism could play a role in the development of chronic pancreatitis and pancreatic cancer through interaction with other genetic and environmental factors. 23 A population-based case-control study showed that ACE I/D polymorphism may alter susceptibility to gall bladder cancer, especially in women. 24 A case-control study suggested that the ACE I/D polymorphism could be a risk factor for patients with lung cancer in Turkey. 25 A case-control study indicated that the ID genotype of the ACE gene might be protective against breast cancer among Brazilian women. 26 A casecontrol study suggested that the DD genotype of the ACE gene might accompany poor prognostic factors and influence the tumor course of breast cancer. 27 A logistic regression and survival analysis of the Rotterdam Study suggested that the ACE I/D polymorphism played an important role in breast cancer risk and disease-free survival in Caucasian postmenopausal women. 28 A case-control study showed that the I/D polymorphism, by affecting the ACE gene expression, was associated with the progress of oral oncogenesis. 29 Another study showed that ACE was expressed locally in gastric cancer and that the I/D polymorphism influenced metastatic behavior. 30 A case-control study showed that the ACE I/D polymorphism might be linked to the development of early gastric cancer. 31 A casecontrol study showed that the ACE I/D polymorphism might be associated with the development of endometrial carcinoma and with the onset of this tumor in younger women. 32 Our results can be plausibly explained biologically, although the exact mechanism is unclear. Subjects with the DD genotype have higher plasma ACE activity compared with those with the ID and II genotypes. 16, 17 Its activity can be blocked by the ACE inhibitors. It is noteworthy that ACE inhibitors have the effect of modifying gene expression, inhibiting proliferation and invasion of cancer cells, reducing endothelial cell migration and angiogenesis in vitro, whereas tumor growth and metastasis were inhibited in vivo. 33 Several mechanisms of action are possible, but inhibition of matrix metalloprotease activity, reduced expression of vascular endothelial growth factor and interference with the renin-angiotensin system have been demonstrated in experimental studies. 33 Although an association between ACE I/D polymorphism and glioma is biologically plausible, this is the first epidemiological study to evaluate the potential association between ACE I/D polymorphism and glioma.
Some limitations of this study should be mentioned. First of all, the interactions between gene-gene, geneenvironment and even different polymorphic loci of the same gene may modulate glioma risk. Second, this is a hospital-based case-control study, so selection bias is not avoidable and the subjects may not be representative of the general population. Third, these results should be interpreted with caution because the population was exclusively from China, which reduces the possibility of confounding from ethnicity; thus the results cannot be extrapolated to other ethnic groups.
Conclusions
In conclusion, our data suggested that the ACE DD genotype was associated with a higher glioma risk in this Chinese population. To the best of our knowledge, this is the first report describing the potential association between ACE I/D polymorphism and glioma. This is an adequate study with potentially useful information. Additional studies are needed to confirm this finding. 
